136 related articles for article (PubMed ID: 36028997)
21. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
22. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.
Krishna S; Lowery FJ; Copeland AR; Bahadiroglu E; Mukherjee R; Jia L; Anibal JT; Sachs A; Adebola SO; Gurusamy D; Yu Z; Hill V; Gartner JJ; Li YF; Parkhurst M; Paria B; Kvistborg P; Kelly MC; Goff SL; Altan-Bonnet G; Robbins PF; Rosenberg SA
Science; 2020 Dec; 370(6522):1328-1334. PubMed ID: 33303615
[TBL] [Abstract][Full Text] [Related]
23. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
24. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
25. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
26. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
27. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
28. Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.
Forget MA; Malu S; Liu H; Toth C; Maiti S; Kale C; Haymaker C; Bernatchez C; Huls H; Wang E; Marincola FM; Hwu P; Cooper LJ; Radvanyi LG
J Immunother; 2014; 37(9):448-60. PubMed ID: 25304728
[TBL] [Abstract][Full Text] [Related]
29. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
Pellom ST; Dudimah DF; Thounaojam MC; Uzhachenko RV; Singhal A; Richmond A; Shanker A
Oncotarget; 2017 Jan; 8(5):8604-8621. PubMed ID: 28052005
[TBL] [Abstract][Full Text] [Related]
31. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
[TBL] [Abstract][Full Text] [Related]
32. Thymocyte selection-associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway.
Niu H; Zhang M; Liu M; Yang L; Yang L; Ren J; Yu Y; Liu Y; Xing L; Shao Z; Wang H
Hematol Oncol; 2024 Jan; 42(1):e3224. PubMed ID: 37712442
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.
Pitt SC; Chen H; Kunnimalaiyaan M
Ann Surg Oncol; 2009 Oct; 16(10):2936-42. PubMed ID: 19588205
[TBL] [Abstract][Full Text] [Related]
34. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Schiltz PM; Beutel LD; Nayak SK; Dillman RO
J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
[TBL] [Abstract][Full Text] [Related]
35. N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.
Scheffel MJ; Scurti G; Wyatt MM; Garrett-Mayer E; Paulos CM; Nishimura MI; Voelkel-Johnson C
Cancer Immunol Immunother; 2018 Apr; 67(4):691-702. PubMed ID: 29396710
[TBL] [Abstract][Full Text] [Related]
36. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
37. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
[TBL] [Abstract][Full Text] [Related]
38. Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8
Abu Eid R; Friedman KM; Mkrtichyan M; Walens A; King W; Janik J; Khleif SN
Oncoimmunology; 2015 May; 4(5):e1005448. PubMed ID: 26155399
[TBL] [Abstract][Full Text] [Related]
39. 4-1BB signaling activates the t cell factor 1 effector/β-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T Cells.
Lee DY; Choi BK; Lee DG; Kim YH; Kim CH; Lee SJ; Kwon BS
PLoS One; 2013; 8(7):e69677. PubMed ID: 23874982
[TBL] [Abstract][Full Text] [Related]
40. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
De Marco C; Rinaldo N; Bruni P; Malzoni C; Zullo F; Fabiani F; Losito S; Scrima M; Marino FZ; Franco R; Quintiero A; Agosti V; Viglietto G
PLoS One; 2013; 8(2):e55362. PubMed ID: 23408974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]